NVCR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
193.4M
+5.3%
183.6M
+5.5%
174.1M
-0.2%
174.3M
+4.3%
167.2M
Cost of Revenue
44.5M
+8.3%
41.1M
+5.6%
38.9M
-7.7%
42.2M
-5.8%
44.7M
Gross Profit
148.9M
+4.5%
142.5M
+5.4%
135.1M
+2.2%
132.2M
+7.9%
122.5M
Operating Expenses
155.0M
+1.3%
153.0M
-24.4%
202.5M
+17.4%
172.6M
+8.9%
158.5M
R&D
58.1M
+12.9%
51.4M
-11.8%
58.3M
-4.2%
60.9M
+12.7%
54.0M
SG&A
96.9M
-4.6%
101.6M
-29.6%
144.2M
+29.1%
111.7M
+6.9%
104.5M
Operating Income
-6171000
+41.6%
-10562000
+84.3%
-67420000
-66.9%
-40393000
-12.1%
-36021000
EBITDA
-1755000
+71.9%
-6255000
+90.1%
-63296000
-75.0%
-36175000
-11.8%
-32358000
Net Income
-10435000
+33.4%
-15658000
+78.0%
-71138000
-190.4%
-24499000
+34.3%
-37270000
EPS (Basic)
$-0.09
+30.8%
$-0.13
+79.0%
$-0.62
-181.8%
$-0.22
+33.3%
$-0.33
EPS (Diluted)
$-0.09
+30.8%
$-0.13
+79.0%
$-0.62
-181.8%
$-0.22
+33.3%
$-0.33
Shares (Diluted)
116.8M
+0.7%
116.0M
+1.6%
114.1M
+1.8%
112.1M
+0.2%
111.9M
NovoCure (NVCR) — Financials